VYNE Therapeutics (NASDAQ:VYNE) Releases Earnings Results, Misses Estimates By $0.03 EPS

VYNE Therapeutics (NASDAQ:VYNE) issued its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03), Zacks reports. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%.

VYNE Therapeutics Stock Performance

VYNE stock traded up $0.07 during trading on Thursday, reaching $2.38. 38,744 shares of the company traded hands, compared to its average volume of 81,002. The company has a market capitalization of $35.03 million, a price-to-earnings ratio of -2.76 and a beta of 1.13. The business has a 50 day simple moving average of $2.80 and a 200 day simple moving average of $2.50. VYNE Therapeutics has a 12 month low of $1.57 and a 12 month high of $4.30.

Insider Transactions at VYNE Therapeutics

In other VYNE Therapeutics news, Director Patrick G. Lepore bought 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.92 per share, for a total transaction of $43,800.00. Following the purchase, the director now directly owns 51,472 shares in the company, valued at $150,298.24. This represents a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on VYNE. HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a research note on Wednesday, February 19th. BTIG Research initiated coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective on the stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.